United Therapeutics
UTHR • NASDAQ
United Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Martine A. Rothblatt, with a market cap of $22.9B.
CEOMartine A. Rothblatt
Next Earnings
Upcoming earnings announcement for United Therapeutics
Date
Wednesday, April 29, 2026 (in 4 weeks)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$6.73
Revenue Estimate
$806.6M
Earnings History
Past 12 earnings reports for United Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | $7.70Est: $6.77 | +13.7% | $790.2MEst: $808.9M | -2.3% |  10-K |
| Oct 29, 2025 | Q3 2025 | $7.16Est: $6.93 | +3.3% | $799.5MEst: $814.8M | -1.9% | 10-Q |
| Jul 30, 2025 | Q2 2025 | $6.41Est: $6.87 | -6.7% | $798.6MEst: $800.5M | -0.2% | 10-Q |
| Apr 30, 2025 | Q1 2025 | $6.63Est: $6.53 | +1.5% | $794.4MEst: $729.8M | +8.8% | 10-Q |
| Feb 26, 2025 | Q4 2024 | $6.19Est: $6.31 | -1.9% | $735.9MEst: $734.7M | +0.2% | 10-K |
| Oct 30, 2024 | Q3 2024 | $6.39Est: $6.42 | -0.5% | $748.9MEst: $722.6M | +3.6% | 10-Q |
| Jul 31, 2024 | Q2 2024 | $5.85Est: $6.40 | -8.6% | $714.9MEst: $691.9M | +3.3% | 10-Q |
| May 1, 2024 | Q1 2024 | $6.17Est: $5.65 | +9.2% | $677.7MEst: $624.0M | +8.6% | 10-Q |
| Feb 21, 2024 | Q4 2023 | $4.36Est: $4.19 | +4.1% | $614.7MEst: $575.9M | +6.7% | 10-K |
| Nov 1, 2023 | Q3 2023 | $5.38Est: $5.08 | +5.9% | $609.4MEst: $587.9M | +3.7% | — |
| Aug 2, 2023 | Q2 2023 | $5.24Est: $4.41 | +18.8% | $596.5MEst: $532.3M | +12.1% | 10-Q |
| May 3, 2023 | Q1 2023 | $4.86Est: $4.52 | +7.5% | $506.9MEst: $514.4M | -1.5% | — |